Study on Cutoff Revision Effects and Evaluation of NNT in Primary Aldosteronism
Condition(s) studied
Investigational drug(s) / intervention(s)
Saline Infusion Test: Standardized saline infusion test performed for confirmatory diagnosis of primary aldosteronism.
Study summary
The goal of this observational study is to evaluate the real-world impact of applying the revised aldosterone-to-renin ratio (ARR) cutoff recommended in the 2025 primary aldosteronism guideline in adults with hypertension and biochemical findings suggestive of an intermediate probability of lateralizing primary aldosteronism (PA). The main questions it aims to answer are:
* What is the number needed to test (NNT) to diagnose one case of primary aldosteronism when using the revised ARR cutoff (\>20)?
* What is the optimal ARR cutoff for diagnosing PA in Korean patients?
* What is the biochemical treatment response rate at 6 months after treatment for confirmed PA?
Participants will:
* Undergo standardized ARR testing after protocol-based medication adjustment and controlled sampling conditions.
* Undergo confirmatory testing using the saline infusion test (SIT).
* Receive standard clinical management for confirmed PA according to institutional practice.
* Be followed for assessment of biochemical outcomes after treatment.
Eligibility
Primary outcome measure(s)
- Number Needed to Test for Diagnosis of Primary Aldosteronism — Through study completion, an average of 6 months
Number of saline infusion tests required to confirm one case of primary aldosteronism among participants meeting the revised aldosterone-to-renin ratio screening cutoff criteria.
Trial sites (1)
| Facility | City | Region | Status |
|---|---|---|---|
| Seoul National University Hospital | Seoul | Korea, Republic of | Recruiting |
More Seoul National University Hospital trials in South Korea
Other trials for the same condition
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT07621458 on ClinicalTrials.gov ↗ ← All trials in South Korea